Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EnteroMedics Maestro Obesity Management Implant PMA Slated For 2008

This article was originally published in The Gray Sheet

Executive Summary

EnteroMedics expects to file an investigational device exemption with FDA by year end for U.S. trials of its Maestro obesity management implant

You may also be interested in...



Financings In Brief

EnteroMedics plans IPO: Developer of the Maestro obesity management implant files preliminary prospectus May 25 with the Securities & Exchange Commission for an initial public stock offering to help fund preparations for a PMA submission in the first half of 2009. Intended as an alternative to gastric bypass or gastric banding procedures, the system is based on the firm's VBLOC (Vagal Blocking for Obestity Control Therapy) technology, which uses high frequency, low power pulses of electrical energy to block satiety and hunger signals carried by the vagus nerve between the brain and digestive organs. EnteroMedics plans to begin a 220-patient, U.S. pivotal trial by the end of September. The St. Paul, Minn. firm initially planned to file a PMA by mid-2008; the company currently projects FDA approval and a U.S. launch in 2010 (1"The Gray Sheet" Aug. 7, 2006, p. 10)...

Financings In Brief

EnteroMedics plans IPO: Developer of the Maestro obesity management implant files preliminary prospectus May 25 with the Securities & Exchange Commission for an initial public stock offering to help fund preparations for a PMA submission in the first half of 2009. Intended as an alternative to gastric bypass or gastric banding procedures, the system is based on the firm's VBLOC (Vagal Blocking for Obestity Control Therapy) technology, which uses high frequency, low power pulses of electrical energy to block satiety and hunger signals carried by the vagus nerve between the brain and digestive organs. EnteroMedics plans to begin a 220-patient, U.S. pivotal trial by the end of September. The St. Paul, Minn. firm initially planned to file a PMA by mid-2008; the company currently projects FDA approval and a U.S. launch in 2010 (1"The Gray Sheet" Aug. 7, 2006, p. 10)...

Financings In Brief

IntraPace raises funds for obesity control implant: Clinical trials of IntraPace's endoscopically delivered, implantable gastric stimulator for treatment of obesity will commence in 2007, supported by a $30 mil. private placement announced Aug. 14, according to the company. The funds will be used to "complete product development and worldwide clinical studies," IntraPace says. Competing products under development include EnteroMedics' Maestro obesity management implant, in Phase I trials (1"The Gray Sheet" Aug. 7, 2006, p. 10). IntraPace's Series D financing round was led by Vulcan Capital. Additional investors include Boston Scientific, Johnson & Johnson, L Capital Partners, DFJ ePlanet, Oxford Bioscience Partners, Toucan Capital, CB Health Ventures, Halo Fund II and The Angel's Forum...

Related Content

UsernamePublicRestriction

Register

MT023845

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel